A thematic analysis assessing clinical decision-making in antipsychotic prescribing for schizophrenia

Research output: Contribution to journalArticlepeer-review

Standard Standard

A thematic analysis assessing clinical decision-making in antipsychotic prescribing for schizophrenia. / Roberts, Rossela; Neasham, Abigail; Lambrinudi, Chania et al.
In: BMC Psychiatry, Vol. 18, 290, 10.09.2018.

Research output: Contribution to journalArticlepeer-review

HarvardHarvard

APA

CBE

MLA

VancouverVancouver

Roberts R, Neasham A, Lambrinudi C, Khan A. A thematic analysis assessing clinical decision-making in antipsychotic prescribing for schizophrenia. BMC Psychiatry. 2018 Sept 10;18:290. doi: 10.1186/s12888-018-1872-y

Author

Roberts, Rossela ; Neasham, Abigail ; Lambrinudi, Chania et al. / A thematic analysis assessing clinical decision-making in antipsychotic prescribing for schizophrenia. In: BMC Psychiatry. 2018 ; Vol. 18.

RIS

TY - JOUR

T1 - A thematic analysis assessing clinical decision-making in antipsychotic prescribing for schizophrenia

AU - Roberts, Rossela

AU - Neasham, Abigail

AU - Lambrinudi, Chania

AU - Khan, Afshan

PY - 2018/9/10

Y1 - 2018/9/10

N2 - BackgroundIn recent decades atypical antipsychotics have increased treatment options available for schizophrenia, however there is conflicting evidence concerning the trade-off between clinical efficacy and side effects for the different classes of antipsychotics. There has been a consistent increase in atypical antipsychotic prescribing compared to typical, despite evidence showing that neither class is superior. This leads to the question of whether prescribers are selective in their uptake of research evidence and clinical guidelines and if so, what influences their choice.. This study aims to identify the factors that contribute to the prescribing choice and how these can be used to aid knowledge translation and guideline implementation.MethodsA thematic analysis study was conducted using data from 11 semi-structured interviews with clinicians with experience in prescribing for schizophrenia.ResultsThe analysis identified five themes underpinning prescribing behaviour: (1) ownership and collaboration; (2) compromise; (3) patient involvement; (4) integrating research evidence; and (5) experience.ConclusionThe themes mapped to various degrees onto current models of evidence-based decision making and suggest that there is scope to re-think the guideline implementation frameworks to incorporate recurring themes salient to clinicians who ultimately use the guidelines. This will further translation of future evidence into clinical practice, accelerating clinical progress.

AB - BackgroundIn recent decades atypical antipsychotics have increased treatment options available for schizophrenia, however there is conflicting evidence concerning the trade-off between clinical efficacy and side effects for the different classes of antipsychotics. There has been a consistent increase in atypical antipsychotic prescribing compared to typical, despite evidence showing that neither class is superior. This leads to the question of whether prescribers are selective in their uptake of research evidence and clinical guidelines and if so, what influences their choice.. This study aims to identify the factors that contribute to the prescribing choice and how these can be used to aid knowledge translation and guideline implementation.MethodsA thematic analysis study was conducted using data from 11 semi-structured interviews with clinicians with experience in prescribing for schizophrenia.ResultsThe analysis identified five themes underpinning prescribing behaviour: (1) ownership and collaboration; (2) compromise; (3) patient involvement; (4) integrating research evidence; and (5) experience.ConclusionThe themes mapped to various degrees onto current models of evidence-based decision making and suggest that there is scope to re-think the guideline implementation frameworks to incorporate recurring themes salient to clinicians who ultimately use the guidelines. This will further translation of future evidence into clinical practice, accelerating clinical progress.

KW - Antipsychotics Schizophrenia Guidelines Qualitative Evidence based medicine

U2 - 10.1186/s12888-018-1872-y

DO - 10.1186/s12888-018-1872-y

M3 - Article

VL - 18

JO - BMC Psychiatry

JF - BMC Psychiatry

SN - 1471-244X

M1 - 290

ER -